SSII
HealthcareSS Innovations International, Inc. · Medical - Devices · $780M
What is SS Innovations International, Inc.?
SS Innovations International is a small-cap surgical robotics company headquartered in Fort Lauderdale, Florida. It designs robotic surgical systems and supporting instruments aimed at improving precision in minimally invasive procedures, including cardiac surgery.
SS Innovations develops and commercializes robotic surgery platforms and associated surgical instruments. Its systems are designed to give surgeons enhanced visualization and control during complex procedures. Revenue is generated through the sale and deployment of robotic surgical hardware and the instruments that accompany those platforms. The company targets hospitals and surgical centers seeking to expand their robotic surgery capabilities, competing in a market historically dominated by larger, more established players.
The company was founded in 2018 and is based in Fort Lauderdale, Florida.
- SSI Mantra surgical robotic system for minimally invasive procedures
- SSI Mudra range of robotic surgical instruments including cardiac surgery support
- SSI Maya robotic surgery platform
- OMNI 3D HD live three-dimensional high-definition surgical visualization system
Is SSII a Good Stock to Buy?
UQS Score rates SSII as Poor overall, reflecting meaningful structural challenges despite some brighter spots in its profile.
The Growth pillar stands out as a relative positive, suggesting the company is expanding its footprint in the surgical robotics space. The Risk pillar also registers as Good, indicating the near-term financial risk profile is not as alarming as the overall score might suggest.
Both the Quality and Moat pillars are rated Weak, pointing to thin business durability and limited competitive insulation — significant concerns for a company still establishing itself. Valuation is rated Elevated, meaning the market may already be pricing in optimistic outcomes.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does SSII pay dividends?
No — SS Innovations International, Inc. does not currently pay a dividend.
SSII does not currently pay a dividend. As an early-stage surgical robotics company, capital is directed toward product development, commercialization, and building out its platform portfolio rather than returning cash to shareholders. Investors drawn to this stock are typically focused on growth potential rather than income.
When does SSII report earnings?
SS Innovations International reports earnings on a quarterly cadence, consistent with US-listed public companies.
Given the company's early commercial stage, quarterly results tend to reflect investment in platform development and market expansion rather than mature profitability. Revenue trajectory and cash consumption are the key metrics investors watch each reporting period.
For the most recent quarter's results, visit SS Innovations International's investor relations page directly.
SSII Price History
+360.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in SS Innovations International, Inc.?
Based on SS Innovations International, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
SSII Long-term Outlook
The UQS Growth pillar suggests SSII is on an upward trajectory in terms of business expansion, which is consistent with a company actively commercializing new surgical robotics platforms. However, the Weak Quality and Moat ratings temper that optimism — growth without durable competitive advantages can be difficult to sustain. The Elevated Valuation rating adds another layer of caution, as the current market price may leave limited room for error if execution stumbles.
Growth drivers
- Expanding adoption of robotic surgery in emerging and mid-tier hospital markets
- Growing portfolio of platforms and instruments addressing multiple surgical specialties
- Rising global demand for minimally invasive surgical solutions
Key risks
- Weak competitive moat against larger, entrenched surgical robotics players
- Elevated valuation leaves little margin of safety if growth disappoints
- Early-stage quality metrics suggest operational and financial fragility
SSII vs Peers
SSII operates in a competitive medical device landscape alongside companies that address adjacent surgical and therapeutic needs.
InMode focuses on energy-based minimally invasive aesthetic and surgical platforms, operating in a different clinical niche with an established commercial footprint.
Integra is a diversified medical technology company with a broad neurosurgery and reconstructive portfolio, giving it scale advantages SSII has yet to build.
Avanos specializes in pain management and respiratory health solutions, competing more broadly in the medical device space rather than surgical robotics specifically.
Frequently Asked Questions
What does SS Innovations International do?
SS Innovations International develops surgical robotic systems and instruments designed to assist surgeons during complex, minimally invasive procedures. Its product portfolio includes robotic surgery platforms and a 3D HD visualization system for operating rooms. The company targets hospitals and surgical centers looking to adopt or expand robotic surgery capabilities.
Does SSII pay dividends?
SSII does not pay a dividend. The company is in an early commercial stage and allocates resources toward product development and market expansion. Investors in SSII are generally seeking growth exposure rather than income from distributions.
When does SSII report earnings?
SS Innovations International reports on a quarterly cadence, as is standard for US-listed companies. For exact reporting dates and the most recent financial results, check the company's investor relations page directly.
Is SSII a good stock to buy?
UQS Score rates SSII as Poor overall. While the Growth and Risk pillars show relative strength, the Weak Quality and Moat ratings alongside an Elevated Valuation present meaningful concerns. Investors should weigh these factors carefully. The full pillar breakdown is available to UQS Pro members.
Is SSII overvalued?
The UQS Valuation pillar for SSII is rated Elevated, suggesting the current market price may reflect optimistic assumptions about the company's growth trajectory. For a company still building its commercial foundation, an elevated valuation leaves limited buffer if execution falls short of expectations.
How does SSII compare to its competitors?
SSII is a smaller, earlier-stage player compared to more established medical device companies. Competitors like Integra LifeSciences carry broader portfolios and greater scale. SSII's differentiation lies in its focused surgical robotics platform approach, though its Weak Moat rating signals that competitive insulation remains limited at this stage.
What is SSII's market cap bracket?
SSII is classified as a small-cap stock. This places it in a category where liquidity can be lower and price volatility higher than large- or mega-cap peers. Small-cap healthcare companies often carry elevated risk alongside their growth potential.
Who founded SS Innovations International?
SS Innovations International was founded in 2018. For detailed founding history and leadership background, the company's official website and public filings are the most reliable sources.
Is SSII a long-term quality stock?
As a long-term quality indicator, SSII's UQS profile raises caution. The Weak Quality and Moat pillars suggest the business has not yet built the durable characteristics — consistent profitability, competitive advantages — typically associated with long-term compounders. The Growth pillar offers some encouragement, but quality foundations matter for sustained performance.
What is the main competitive advantage of SS Innovations International?
SSII's potential advantage lies in offering surgical robotic platforms targeted at markets underserved by dominant incumbents. However, the UQS Moat pillar is currently rated Weak, indicating that any competitive edge has not yet translated into durable, measurable insulation from rivals.
What sector does SSII belong to?
SSII operates in the Healthcare sector, specifically within the medical devices and surgical robotics segment. This is a capital-intensive, innovation-driven space where regulatory approval, clinical adoption, and scale all play critical roles in long-term success.
Is SSII a growth stock or value stock?
Based on its UQS profile, SSII leans toward the growth category — the Growth pillar is rated Good, reflecting expansion activity. However, the Elevated Valuation rating means investors are already paying a premium for that growth, which reduces the margin of safety typically associated with value-oriented investing.
Unlock Full SSII Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics behind each pillar rating
- ✓Compare SSII against sector peers on quality and growth
- ✓Track valuation changes as new data is published
- ✓Get the full analyst view available to Pro members
Pro Analysis
SSII — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 16, 2026 | 27.4 | 10.8 | 23.0 | 62.5 | 42.7 | 0.0 | -3.1 |
| Apr 2, 2026 | 30.5 | 10.4 | 23.0 | 62.5 | 64.1 | 0.0 | — |
SSII — Pillar Breakdown
Quality
— 10.8/100 (25%)SS Innovations International, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 62.5/100 (20%)SS Innovations International, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 42.7/100 (15%)SS Innovations International, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)SS Innovations International, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 23/100 (25%)SS Innovations International, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for SSII.
Score Composition
Financial Data
More Stock Analysis
How is the SSII UQS Score Calculated?
The UQS (Unified Quality Score) for SS Innovations International, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses SS Innovations International, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether SS Innovations International, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.